CpG oligodeoxynucleotide-based therapy of lymphoid malignancies

Advanced Drug Delivery Reviews

Volumn 61, Issue 3, 2009, Pages 263-267

  Weiner, George J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

B cell; CpG ODN; Lymphoid malignancies; TLR 9

Indexed keywords

ACTIVATION-INDUCED CELL DEATHS; ANTIGEN PRESENTING CELLS; B CELL; CLINICAL TRIALS; CPG ODN; CYTOKINES; DENDRITIC CELLS; DINUCLEOTIDES; IMMUNE RESPONSE; INDIRECT EFFECTS; LYMPHOID MALIGNANCIES; MALIGNANT CELLS; OLIGODEOXYNUCLEOTIDE; OLIGODEOXYNUCLEOTIDES; PRECLINICAL STUDIES; TARGET CELLS; TARGET RECEPTORS; TLR 9; TOLL-LIKE RECEPTOR 9; UP REGULATIONS; VACCINATION STRATEGIES;

ANTIGENS; CELL DEATH; DENDRIMERS; INTERNET;

TARGETS;

AGATOLIMOD; ALPHA INTERFERON; CD20 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; CYTOKINE RECEPTOR; IBRITUMOMAB TIUXETAN; RITUXIMAB; TOLL LIKE RECEPTOR 9; YTTRIUM 90;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; DENDRITIC CELL; DOSE RESPONSE; DRUG MECHANISM; DRUG TOLERABILITY; FLU LIKE SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; IMMUNOTHERAPY; INJECTION SITE REACTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; ANTIGENS, CD20; B-LYMPHOCYTES; COMBINED MODALITY THERAPY; CPG ISLANDS; HUMANS; LYMPHOMA, B-CELL; OLIGODEOXYRIBONUCLEOTIDES; RADIOIMMUNOTHERAPY; TOLL-LIKE RECEPTOR 9;

EID: 61849161673     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2008.12.006     Document Type: Review

References (39)

1. Coley W.B. The treatment of malignant tumors by repeated inoculations of Erysipelas with a report of ten original cases. Am. J. Med. Sci. 105 (1893) 487-511
2. Krieg A.M., Yi A.K., Matson S., Waldschmidt T.J., Bishop G.A., Teasdale R., Koretzky G.A., and Klinman D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 6522 (1995) 546-549
3. Winter J.N. Defining the role of immunotherapy and radioimmunotherapy in the treatment of low-grade lymphoma. Curr. Opin. Hematol. 14 4 (2007) 360-368
4. Lowder J.N., Meeker T.C., Campbell M., Garcia C.F., Gralow J., Miller R.A., Warnke R., and Levy R. Studies on B lymphoid tumors treated with monoclonal anti-idiotype antibodies: correlation with clinical responses. Blood 69 1 (1987) 199-210
5. Decker T., Schneller F., Sparwasser T., Tretter T., Lipford G.B., Wagner H., and Peschel C. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 95 3 (2000) 999-1006
6. Jahrsdorfer B., Jox R., Muhlenhoff L., Tschoep K., Krug A., Rothenfusser S., Meinhardt G., Emmerich B., Endres S., and Hartmann G. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J. Leukoc. Biol. 72 1 (2002) 83-92
7. Jahrsdorfer B., Muhlenhoff L., Blackwell S.E., Wagner M., Poeck H., Hartmann E., Jox R., Giese T., Emmerich B., Endres S., Weiner G.J., and Hartmann G. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin. Cancer Res. 11 4 (2005) 1490-1499
8. Dicker F., Schnittger S., Haferlach T., Kern W., and Schoch C. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 108 9 (2006) 3152-3160
9. Longo P.G., Laurenti L., Gobessi S., Petlickovski A., Pelosi M., Chiusolo P., Sica S., Leone G., and Efremov D.G. The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. Leukemia 21 1 (2007) 110-120
10. Castro J.E., Prada C.E., Aguillon R.A., Kitada S., Fukuda T., Motta M., Wu C., Dicker F., Sun G., Wang J.Y., Carson D.A., Reed J.C., and Kipps T.J. Thymidine-phosphorothioate oligonucleotides induce activation and apoptosis of CLL cells independently of CpG motifs or BCL-2 gene interference. Leukemia 20 4 (2006) 680-688
11. Jahrsdorfer B., Wooldridge J.E., Blackwell S.E., Taylor C.M., Griffith T.S., Link B.K., and Weiner G.J. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J. Leukoc. Biol. 77 3 (2005) 378-387
12. Jahrsdorfer B., Wooldridge J.E., Blackwell S.E., Taylor C.M., Link B.K., and Weiner G.J. Good prognosis cytogenetics in B-cell chronic lymphocytic leukemia is associated in vitro with low susceptibility to apoptosis and enhanced immunogenicity. Leukemia 19 5 (2005) 759-766
13. Carpentier A., Laigle-Donadey F., Zohar S., Capelle L., Behin A., Tibi A., Martin-Duverneuil N., Sanson M., Lacomblez L., Taillibert S., Puybasset L., Van Effenterre R., Delattre J.Y., and Carpentier A.F. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-Oncology 8 1 (2006) 60-66
14. Bradbury P.A., and Shepherd F.A. Immunotherapy for lung cancer. J. Thorac. Oncol. 3 6 Suppl 2 (2008) S164-170
15. Hofmann M.A., Kors C., Audring H., Walden P., Sterry W., and Trefzer U. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J. Immunother. 31 5 (2008) 520-527
16. Molenkamp B.G., Sluijter B.J., van Leeuwen P.A., Santegoets S.J., Meijer S., Wijnands P.G., Haanen J.B., van den Eertwegh A.J., Scheper R.J., and de Gruijl T.D. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin. Cancer Res. 14 14 (2008) 4532-4542
17. Molenkamp B.G., van Leeuwen P.A., Meijer S., Sluijter B.J., Wijnands P.G., Baars A., van den Eertwegh A.J., Scheper R.J., and de Gruijl T.D. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin. Cancer Res. 13 10 (2007) 2961-2969
18. Murad Y.M., Clay T.M., Lyerly H.K., and Morse M.A. CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Exp. Opin. Biol. Ther. 7 8 (2007) 1257-1266
19. Pashenkov M., Goess G., Wagner C., Hormann M., Jandl T., Moser A., Britten C.M., Smolle J., Koller S., Mauch C., Tantcheva-Poor I., Grabbe S., Loquai C., Esser S., Franckson T., Schneeberger A., Haarmann C., Krieg A.M., Stingl G., and Wagner S.N. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol. 24 36 (2006) 5716-5724
20. Stoeter D., de Liguori Carino N., Marshall E., Poston G.J., and Wu A. Extensive necrosis of visceral melanoma metastases after immunotherapy. World J. Surg. Oncol. 6 (2008) 30
21. Link B.K., Ballas Z.K., Weisdorf D., Wooldridge J.E., Bossler A.D., Shannon M., Rasmussen W.L., Krieg A.M., and Weiner G.J. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother. 29 5 (2006) 558-568
22. Jahrsdorfer B., Hartmann G., Racila E., Jackson W., Muhlenhoff L., Meinhardt G., Endres S., Link B.K., Krieg A.M., and Weiner G.J. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J. Leukoc. Biol. 69 1 (2001) 81-88
23. Decker T., Schneller F., Kronschnabl M., Dechow T., Lipford G.B., Wagner H., and Peschel C. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells. Costimulation with IL-2 results in a highly immunogenic phenotype. Exp. Hematol. 28 5 (2000) 558-568
24. Jahrsdorfer B., Blackwell S.E., Wooldridge J.E., Huang J., Andreski M.W., Jacobus L.S., Taylor C.M., and Weiner G.J. B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after Interleukin-21-based activation. Blood 108 8 (2006) 2712-2719
25. Maloney D.G. Preclinical and phase I and II trials of rituximab. Semin. Oncol. 26 5 Suppl 14 (1999) 74-78
26. Friedberg J.W., Kim H., McCauley M., Hessel E.M., Sims P., Fisher D.C., Nadler L.M., Coffman R.L., and Freedman A.S. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 105 2 (2005) 489-495
27. Leonard J.P., Link B.K., Emmanouilides C., Gregory S.A., Weisdorf D., Andrey J., Hainsworth J., Sparano J.A., Tsai D.E., Horning S., Krieg A.M., and Weiner G.J. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin. Cancer Res. 13 20 (2007) 6168-6174
28. Witzig T.E., White C.A., Wiseman G.A., Gordon L.I., Emmanouilides C., Raubitschek A., Janakiraman N., Gutheil J., Schilder R.J., Spies S., Silverman D.H., Parker E., and Grillo-Lopez A.J. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 17 12 (1999) 3793-3803
29. Kaminski M.S., Zasadny K.R., Francis I.R., Milik A.W., Ross C.W., Moon S.D., Crawford S.M., Burgess J.M., Petry N.A., Butchko G.M., et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329 7 (1993) 459-465
30. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., and Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. U. S. A. 94 20 (1997) 10833-10837
31. Liu H.M., Newbrough S.E., Bhatia S.K., Dahle C.E., Krieg A.M., and Weiner G.J. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood 92 10 (1998) 3730-3736
32. Foon K.A., Roth M.S., and Bunn Jr. P.A. Interferon therapy of non-Hodgkin's lymphoma. Cancer 59 3 Suppl (1987) 601-604
33. Kimby E. Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte colony stimulating factor. Semin. Oncol. 29 2 Suppl 6 (2002) 7-10
34. Vollmer J., Weeratna R., Payette P., Jurk M., Schetter C., Laucht M., Wader T., Tluk S., Liu M., Davis H.L., and Krieg A.M. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 34 1 (2004) 251-262
35. Ballas Z.K., Krieg A.M., Warren T., Rasmussen W., Davis H.L., Waldschmidt M., and Weiner G.J. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167 9 (2001) 4878-4886
36. Jahrsdorfer B., Blackwell S.E., Wooldridge J.E., Taylor C.M., and Weiner G.J. Serum alters the uptake and biologic activity of CpG oligodeoxynucleotides in B cell chronic lymphocytic leukemia. Oligonucleotides 15 1 (2005) 51-59
37. Heckelsmiller K., Rall K., Beck S., Schlamp A., Seiderer J., Jahrsdorfer B., Krug A., Rothenfusser S., Endres S., and Hartmann G. Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J. Immunol. 169 7 (2002) 3892-3899
38. Zhang X.Q., Dahle C.E., Baman N.K., Rich N., Weiner G.J., and Salem A.K. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J. Immunother. (1997) 30 5 (2007) 469-478
39. Zhang X.Q., Dahle C.E., Weiner G.J., and Salem A.K. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles. J. Pharm. Sci. 96 12 (2007) 3283-3292